1
|
Carmi L, Zohar J, Juven-Wetzler A, Desarnaud F, Makotkine L, Bierer LM, Cohen H, Yehuda R. Promoter methylation of the glucocorticoid receptor following trauma may be associated with subsequent development of PTSD. World J Biol Psychiatry 2023; 24:578-586. [PMID: 36748398 PMCID: PMC10440098 DOI: 10.1080/15622975.2023.2177342] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/11/2022] [Revised: 01/22/2023] [Accepted: 02/02/2023] [Indexed: 02/08/2023]
Abstract
OBJECTIVES The ability to identify persons at elevated risk for post-traumatic stress disorder (PTSD) soon after exposure to trauma, could aid clinical decision-making and treatment. In this study, we explored whether cytosine methylation of the 1 F promoter of the NR3C1 (glucocorticoid receptor [GR]) gene obtained immediately following a trauma could predict PTSD. METHODS Our sample comprised 52 trauma survivors (28 women, 24 men), presenting to the Emergency Department (ED) within six hours of a traumatic event and followed for 13 months. Blood samples were taken at intake (n = 42) and again at the end of the study (13 months later, n = 27) to determine NR3C1-1F promoter methylation as well as plasma levels of cortisol, adrenocorticotropic-hormone (ACTH), and neuropeptide-Y (NPY). RESULTS At the 13-month follow-up, participants who met the PTSD criteria (n = 4) showed significantly lower NR3C1-1F promoter sum percent methylation compared to the non-PTSD group (n = 38). Further, NR3C1-1F methylation at ED intake was inversely correlated with PTSD severity 13 months later, indicating that lower NR3C1-1F promoter methylation in the immediate aftermath of trauma was associated with the development of PTSD. CONCLUSION To the extent that reduced promoter methylation is associated with greater GR expression and responsivity, this finding is consistent with the hypothalamic-pituitary-adrenal dysregulation previously described for PTSD.
Collapse
Affiliation(s)
- Lior Carmi
- Post Trauma Center, Chaim Sheba Medical Center, Ramat Gan, Israel
- The Data Science Institution, Reichman University, Herzliya, Israel
| | - Joseph Zohar
- Post Trauma Center, Chaim Sheba Medical Center, Ramat Gan, Israel
- Tel Aviv University, Tel Aviv, Israel
| | | | - Frank Desarnaud
- Traumatic Stress Studies Division, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, Mental Health Care Center, PTSD Clinical Research Program & Laboratory of Clinical Neuroendocrinology and Neurochemistry, James J. Peters Veterans Affairs Medical Center, Bronx, New York
| | - Louri Makotkine
- Traumatic Stress Studies Division, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, Mental Health Care Center, PTSD Clinical Research Program & Laboratory of Clinical Neuroendocrinology and Neurochemistry, James J. Peters Veterans Affairs Medical Center, Bronx, New York
| | - Linda M Bierer
- Traumatic Stress Studies Division, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, Mental Health Care Center, PTSD Clinical Research Program & Laboratory of Clinical Neuroendocrinology and Neurochemistry, James J. Peters Veterans Affairs Medical Center, Bronx, New York
| | - Hagit Cohen
- Beer-Sheva Mental Health Center, Ministry of Health, Anxiety and Stress Research Unit, Faculty of Health Sciences, Ben-Gurion University of the Negev, Israel
| | - Rachel Yehuda
- Traumatic Stress Studies Division, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, Mental Health Care Center, PTSD Clinical Research Program & Laboratory of Clinical Neuroendocrinology and Neurochemistry, James J. Peters Veterans Affairs Medical Center, Bronx, New York
| |
Collapse
|
2
|
Barzilay S, Fine S, Akhavan S, Haruvi-Catalan L, Apter A, Brunstein-Klomek A, Carmi L, Zohar M, Kinarty I, Friedman T, Fennig S. Real-Time Real-World Digital Monitoring of Adolescent Suicide Risk During the Six Months Following Emergency Department Discharge: Protocol for an Intensive Longitudinal Study. JMIR Res Protoc 2023; 12:e46464. [PMID: 37358906 DOI: 10.2196/46464] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2023] [Revised: 05/28/2023] [Accepted: 05/29/2023] [Indexed: 06/27/2023] Open
Abstract
BACKGROUND Suicide is the second leading cause of death in adolescents, and self-harm is one of the strongest predictors of death by suicide. The rates of adolescents presenting to emergency departments (EDs) for suicidal thoughts and behaviors (STBs) have increased. Still, existing follow-up after ED discharge is inadequate, leaving a high-risk period for reattempts and suicide. There is a need for innovative evaluation of imminent suicide risk factors in these patients, focusing on continuous real-time evaluations with low assessment burden and minimal reliance on patient disclosure of suicidal intent. OBJECTIVE This study examines prospective longitudinal associations between observed real-time mobile passive sensing, including communication and activity patterns, and clinical and self-reported assessments of STB over 6 months. METHODS This study will include 90 adolescents recruited on their first outpatient clinic visit following their discharge from the ED due to a recent STB. Participants will complete brief weekly assessments and be monitored continuously for their mobile app usage, including mobility, activity, and communication patterns, over 6 months using the iFeel research app. Participants will complete 4 in-person visits for clinical assessment at baseline and at the 1-, 3-, and 6-month follow-ups. The digital data will be processed, involving feature extraction, scaling, selection, and dimensionality reduction. Passive monitoring data will be analyzed using both classical machine learning models and deep learning models to identify proximal associations between real-time observed communication, activity patterns, and STB. The data will be split into a training and validation data set, and predictions will be matched against the clinical evaluations and self-reported STB events (ie, labels). To use both labeled and unlabeled digital data (ie, passively collected), we will use semisupervised methods in conjunction with a novel method that is based on anomaly detection notions. RESULTS Participant recruitment and follow-up started in February 2021 and are expected to be completed by 2024. We expect to find prospective proximal associations between mobile sensor communication, activity data, and STB outcomes. We will test predictive models for suicidal behaviors among high-risk adolescents. CONCLUSIONS Developing digital markers of STB in a real-world sample of high-risk adolescents presenting to ED can inform different interventions and provide an objective means to assess the risk of suicidal behaviors. The results of this study will be the first step toward large-scale validation that may lead to suicide risk measures that aid psychiatric follow-up, decision-making, and targeted treatments. This novel assessment could facilitate timely identification and intervention to save young people's lives. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) DERR1-10.2196/46464.
Collapse
Affiliation(s)
- Shira Barzilay
- Department of Community Mental Health, University of Haifa, Haifa, Israel
- Schneider Children's Medical Center of Israel, Petach Tikva, Israel
| | - Shai Fine
- Data Science Institute, Reichman University, Herzliya, Israel
| | - Shannel Akhavan
- Schneider Children's Medical Center of Israel, Petach Tikva, Israel
| | | | - Alan Apter
- Schneider Children's Medical Center of Israel, Petach Tikva, Israel
| | | | - Lior Carmi
- Data Science Institute, Reichman University, Herzliya, Israel
| | - Mishael Zohar
- Data Science Institute, Reichman University, Herzliya, Israel
| | - Inbar Kinarty
- Data Science Institute, Reichman University, Herzliya, Israel
| | - Talia Friedman
- Data Science Institute, Reichman University, Herzliya, Israel
| | - Silvana Fennig
- Schneider Children's Medical Center of Israel, Petach Tikva, Israel
| |
Collapse
|
3
|
Carmi L, Zohar M, Riva GM. The European General Data Protection Regulation (GDPR) in mHealth: Theoretical and practical aspects for practitioners' use. Med Sci Law 2023; 63:61-68. [PMID: 35950240 DOI: 10.1177/00258024221118411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
The extensive use of smart technology (smartphones and wearables) and the vast amount of information they contain have positioned remote devices and technology as a massive database resource. Harnessing these big data into the clinical and research fields has introduced a new horizon of possibilities along with significant privacy issues. A significant evolution in this respect has been the introduction of the new European Union (EU) General Data Protection Regulation (GDPR). The GDPR acknowledges that information related to individuals (i.e. personal data), as well as data flow, and thus databases, are of high political, clinical, and economic value. Hence, the Regulation aims to protect personal data and, consequentially, privacy. Nevertheless, the GDPR is a legal document with legal language. The purpose of this paper is to serve as a - practical guidance as well as a theoretical framework - for clinicians (and non-clinicians) who integrates digital tools in their clinical and research work.
Collapse
Affiliation(s)
- Lior Carmi
- The Data Science Institution, 42727Reichman University, Herzliya, Israel
| | - Mishael Zohar
- The Data Science Institution, 42727Reichman University, Herzliya, Israel
| | - Gianluigi M Riva
- 8797University College Dublin, School of Information and Communication Studies, Dublin, Ireland
| |
Collapse
|
4
|
Fineberg NA, Menchón JM, Hall N, Dell'Osso B, Brand M, Potenza MN, Chamberlain SR, Cirnigliaro G, Lochner C, Billieux J, Demetrovics Z, Rumpf HJ, Müller A, Castro-Calvo J, Hollander E, Burkauskas J, Grünblatt E, Walitza S, Corazza O, King DL, Stein DJ, Grant JE, Pallanti S, Bowden-Jones H, Ameringen MV, Ioannidis K, Carmi L, Goudriaan AE, Martinotti G, Sales CMD, Jones J, Gjoneska B, Király O, Benatti B, Vismara M, Pellegrini L, Conti D, Cataldo I, Riva GM, Yücel M, Flayelle M, Hall T, Griffiths M, Zohar J. Advances in problematic usage of the internet research - A narrative review by experts from the European network for problematic usage of the internet. Compr Psychiatry 2022; 118:152346. [PMID: 36029549 DOI: 10.1016/j.comppsych.2022.152346] [Citation(s) in RCA: 24] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/17/2021] [Revised: 06/29/2022] [Accepted: 08/09/2022] [Indexed: 01/05/2023] Open
Abstract
Global concern about problematic usage of the internet (PUI), and its public health and societal costs, continues to grow, sharpened in focus under the privations of the COVID-19 pandemic. This narrative review reports the expert opinions of members of the largest international network of researchers on PUI in the framework of the European Cooperation in Science and Technology (COST) Action (CA 16207), on the scientific progress made and the critical knowledge gaps remaining to be filled as the term of the Action reaches its conclusion. A key advance has been achieving consensus on the clinical definition of various forms of PUI. Based on the overarching public health principles of protecting individuals and the public from harm and promoting the highest attainable standard of health, the World Health Organisation has introduced several new structured diagnoses into the ICD-11, including gambling disorder, gaming disorder, compulsive sexual behaviour disorder, and other unspecified or specified disorders due to addictive behaviours, alongside naming online activity as a diagnostic specifier. These definitions provide for the first time a sound platform for developing systematic networked research into various forms of PUI at global scale. Progress has also been made in areas such as refining and simplifying some of the available assessment instruments, clarifying the underpinning brain-based and social determinants, and building more empirically based etiological models, as a basis for therapeutic intervention, alongside public engagement initiatives. However, important gaps in our knowledge remain to be tackled. Principal among these include a better understanding of the course and evolution of the PUI-related problems, across different age groups, genders and other specific vulnerable groups, reliable methods for early identification of individuals at risk (before PUI becomes disordered), efficacious preventative and therapeutic interventions and ethical health and social policy changes that adequately safeguard human digital rights. The paper concludes with recommendations for achievable research goals, based on longitudinal analysis of a large multinational cohort co-designed with public stakeholders.
Collapse
Affiliation(s)
- Naomi A Fineberg
- Hertfordshire Partnership University NHS Foundation Trust, Hertfordshire, UK; School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK; School of Clinical Medicine, University of Cambridge, Cambridge, UK.
| | - José M Menchón
- Department of Psychiatry, Bellvitge University Hospital-IDIBELL, University of Barcelona, Cibersam, Barcelona, Spain
| | - Natalie Hall
- Centre for Health Services and Clinical Research, University of Hertfordshire, Hatfield, UK
| | - Bernardo Dell'Osso
- Luigi Sacco University Hospital, Psychiatry 2 Unit, University of Milan, Milan, Italy; "Aldo Ravelli" Center for Nanotechnology and Neurostimulation, University of Milan, Milan, Italy; Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA; Centro per lo studio dei meccanismi molecolari alla base delle patologie neuro-psico-geriatriche", University of Milan, Milan, Italy
| | - Matthias Brand
- General Psychology: Cognition and Center for Behavioral Addiction Research (CeBAR), University of Duisburg-Essen, Germany; Erwin L. Hahn Institute for Magnetic Resonance Imaging, Essen, Germany
| | - Marc N Potenza
- Departments of Psychiatry, Neuroscience and Child Study, Yale University School of Medicine, and Wu Tsai Institute, Yale University, New Haven, USA, New Haven, USA; Connecticut Council on Problem Gambling, Wethersfield, USA; Connecticut Mental Health Center, New Haven, USA
| | - Samuel R Chamberlain
- Department of Psychiatry, Faculty of Medicine, University of Southampton, UK; Southern Health NHS Foundation Trust, Southampton, UK
| | - Giovanna Cirnigliaro
- Luigi Sacco University Hospital, Psychiatry 2 Unit, University of Milan, Milan, Italy
| | - Christine Lochner
- SAMRC Unit on Risk and Resilience in Mental Disorders, Department of Psychiatry, Stellenbosch University, South Africa
| | - Joël Billieux
- Institute of Psychology, University of Lausanne (UNIL), Lausanne, Switzerland
| | - Zsolt Demetrovics
- Centre of Excellence in Responsible Gaming, University of Gibraltar, Gibraltar, Gibraltar; Institute of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary
| | - Hans Jürgen Rumpf
- Department of Psychiatry and Psychotherapy, Translational Psychiatry Unit, Research Group S:TEP (Substance use and related disorders: Treatment, Epidemiology and Prevention) University of Lübeck, Lübeck, Germany
| | - Astrid Müller
- Department of Psychosomatic Medicine and Psychotherapy, Hannover Medical School, Hanover, Germany
| | - Jesús Castro-Calvo
- Department of Personality, Assessment, and Psychological Treatments, University of Valencia, Spain
| | - Eric Hollander
- Autism and Obsessive Compulsive Spectrum Program, Psychiatric Research Institute at Montefiore-Einstein, Albert Einstein College of Medicine
| | - Julius Burkauskas
- Laboratory of Behavioral Medicine, Neuroscience Institute, Lithuanian University of Health Sciences, Vyduno al. 4, 00135 Palanga, Lithuania
| | - Edna Grünblatt
- Department of Child and Adolescent Psychiatry and Psychotherapy, Psychiatric University Hospital Zurich, University of Zurich, Zurich, Switzerland; Neuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland; Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland
| | - Susanne Walitza
- Department of Child and Adolescent Psychiatry and Psychotherapy, Psychiatric University Hospital Zurich, University of Zurich, Zurich, Switzerland; Neuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland; Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland
| | - Ornella Corazza
- Department of Clinical Pharmacological and Biological Science, University of Hertfordshire
| | - Daniel L King
- College of Education, Psychology, & Social Work, Flinders University, Adelaide, Australia
| | - Dan J Stein
- SAMRC Unit on Risk & Resilience in Mental Disorders, Dept of Psychiatry & Neuroscience Institute, University of Cape Town
| | - Jon E Grant
- Department of Psychiatry & Behavioral Neuroscience, University of Chicago
| | - Stefano Pallanti
- Albert Einstein College of Medicine and Montefiore Medical Center, New York, USA; INS Istituto di Neuroscienze, Florence, Italy
| | | | - Michael Van Ameringen
- Deptartment of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Canada
| | - Konstantinos Ioannidis
- Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK; Department of International Health, Care and Public Health Research Institute, Maastricht University, Maastricht, the Netherlands
| | - Lior Carmi
- Post-Trauma Center, Sheba Medical Center, Tel Aviv University, Israel; Reichman University, The Data Science Institution, Herzliya, Israel
| | - Anna E Goudriaan
- Amsterdam UMC, Department of Psychiatry, University of Amsterdam, Amsterdam, the Netherlands; Amsterdam Institute for Addiction Research & Arkin, the Netherlands
| | - Giovanni Martinotti
- Department of Neuroscience, Imaging and Clinical Sciences, G. D'Annunzio University, Chieti, Italy
| | - Célia M D Sales
- Faculty of Psychology and Education Sciences, University of Porto, Porto, Portugal; Center for Psychology at University of Porto (CPUP), University of Porto, Porto, Portugal
| | - Julia Jones
- School of Health and Social Work, University of Hertfordshire, Hatfield, UK
| | | | - Orsolya Király
- Institute of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary
| | - Beatrice Benatti
- Luigi Sacco University Hospital, Psychiatry 2 Unit, University of Milan, Milan, Italy; "Aldo Ravelli" Center for Nanotechnology and Neurostimulation, University of Milan, Milan, Italy
| | - Matteo Vismara
- Luigi Sacco University Hospital, Psychiatry 2 Unit, University of Milan, Milan, Italy; "Aldo Ravelli" Center for Nanotechnology and Neurostimulation, University of Milan, Milan, Italy
| | - Luca Pellegrini
- Hertfordshire Partnership University NHS Foundation Trust, Hertfordshire, UK; School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK
| | - Dario Conti
- Hertfordshire Partnership University NHS Foundation Trust, Hertfordshire, UK; Luigi Sacco University Hospital, Psychiatry 2 Unit, University of Milan, Milan, Italy
| | - Ilaria Cataldo
- Department of Psychology and Cognitive Science, University of Trento, Trento, Italy
| | - Gianluigi M Riva
- School of Information and Communication Studies, University College Dublin
| | - Murat Yücel
- Brain Park, Turner Institute for Brain and Mental Health, School of Psychological Sciences, and Monash Biomedical Imaging Facility, Monash University, Melbourne, Victoria, Australia
| | - Maèva Flayelle
- Institute of Psychology, University of Lausanne, Lausanne, Switzerland
| | | | | | - Joseph Zohar
- Post-Trauma Center, Sheba Medical Center, Tel Aviv University, Israel
| |
Collapse
|
5
|
Carmi L, Zohar J, Weissman T, Juven-Wetzler A, Bierer L, Yehuda R, Cohen H. Hydrocortisone in the emergency department: a prospective, double-blind, randomized, controlled posttraumatic stress disorder study. Hydrocortisone during golden hours. CNS Spectr 2022; 28:1-7. [PMID: 35678177 DOI: 10.1017/s1092852922000852] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
OBJECTIVES A blunted response of the hypothalamic-pituitary-adrenal axis immediately after exposure to traumatic events has been proposed as a risk factor for posttraumatic stress disorder (PTSD). Accordingly, administration of hydrocortisone in the aftermath of a traumatic event is indicated. This study consisted of a randomized, placebo-controlled, double-blind trial investigating whether a single intravenous dose of hydrocortisone administered within 6 hours after exposure to trauma would reduce the incidence of PTSD at the 13-month follow-up. METHODS A total of 118 consented patients with acute stress symptoms were administered a single intravenous bolus of hydrocortisone/placebo within 6 hours of the traumatic event. Blood samples were taken before hydrocortisone administration. RESULTS At 13 months, the hydrocortisone group did not differ from the placebo group regarding PTSD prevalence or symptom severity. However, a significant interaction between time of the trauma (ie, night, when cortisol's level is low) and treatment was found. Specifically, a lower prevalence of PTSD was found at the 13-month follow-up in the hydrocortisone night group. CONCLUSIONS Administration of hydrocortisone within 6 hours of the traumatic event was not effective in preventing PTSD compared to placebo. However, nocturnal administration (when cortisol levels are low) may suggest a new venue for research.
Collapse
Affiliation(s)
- Lior Carmi
- Post Trauma Center, Chaim Sheba Medical Center, Ramat Gan, Israel
- The Data Science Institution, The Inter Disciplinary Center, Herzliya, Israel
| | - Joseph Zohar
- Post Trauma Center, Chaim Sheba Medical Center, Ramat Gan, Israel
| | - Tal Weissman
- Post Trauma Center, Chaim Sheba Medical Center, Ramat Gan, Israel
| | | | - Linda Bierer
- Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Rachel Yehuda
- Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- PTSD Clinical Research Program & Laboratory of Clinical Neuroendocrinology and Neurochemistry, James J. Peters Veterans Affairs Medical Center, New York, NY, USA
| | - Hagit Cohen
- Anxiety and Stress Research Unit, Ben-Gurion University of the Negev, Beer Sheva, Israel
| |
Collapse
|
6
|
Arluk S, Matar MA, Carmi L, Arbel O, Zohar J, Todder D, Cohen H. MDMA treatment paired with a trauma-cue promotes adaptive stress responses in a translational model of PTSD in rats. Transl Psychiatry 2022; 12:181. [PMID: 35504866 PMCID: PMC9064970 DOI: 10.1038/s41398-022-01952-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/16/2021] [Revised: 04/17/2022] [Accepted: 04/21/2022] [Indexed: 11/22/2022] Open
Abstract
MDMA (3,4-methylenedioxymethamphetamine), a synthetic ring-substituted amphetamine, combined with psychotherapy has demonstrated efficacy for the treatment of chronic posttraumatic stress disorder (PTSD) patients. This controlled prospective study aimed to assess the bio-behavioral underpinnings of MDMA in a translational model of PTSD. Rats exposed to predator-scent stress (PSS) were subjected to a trauma-cue at day 7 shortly after single-dose MDMA injection (5 mg/kg). The elevated plus maze and acoustic startle response tests were assessed on day 14 and served for classification into behavioral response groups. Freezing response to a further trauma-reminder was assessed on Day 15. The morphological characteristics of the dentate gyrus (DG) and basolateral amygdala (BLA) were subsequently examined. Hypothalamic-pituitary-adrenal axis and 5-hydroxytryptamine involvement were evaluated using: (1) corticosterone measurements at 2 h and 4 h after MDMA treatment, (2) Lewis strain rats with blunted HPA-response and (3) pharmacological receptor-blockade. MDMA treatment was effective in attenuating stress behavioral responses only when paired with memory reactivation by a trauma-cue. The effects of the treatment on behavior were associated with a commensurate normalization of the dendritic cytoarchitecture of DG and BLA neurons. Pretreatment with RU486, Ketanserin, or Pindolol prevented the above improvement in anxiety-like behavioral responses. MDMA treatment paired with memory reactivation reduced the prevalence rate of PTSD-phenotype 14 days later and normalized the cytoarchitecture changes induced by PSS (in dendritic complexities) compared to saline control. MDMA treatment paired with a trauma-cue may modify or update the original traumatic memory trace through reconsolidation processes. These anxiolytic-like effects seem to involve the HPA axis and 5-HT systems.
Collapse
Affiliation(s)
- Shira Arluk
- Department of Psychology, Ben-Gurion University of the Negev, Beer-Sheva, Israel
| | - Michael A Matar
- Beer-Sheva Mental Health Center, Ministry of Health, Anxiety and Stress Research Unit, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
| | - Lior Carmi
- Post-Trauma Center, Sheba Medical Center, Tel Aviv, Israel
| | - Oded Arbel
- Beer-Sheva Mental Health Center, The Mindfulness Clinic, Beer Sheva, Israel
| | - Joseph Zohar
- Post-Trauma Center, Sheba Medical Center, Tel Aviv, Israel
| | - Doron Todder
- Beer-Sheva Mental Health Center, Ministry of Health, Anxiety and Stress Research Unit, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
| | - Hagit Cohen
- Department of Psychology, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
- Beer-Sheva Mental Health Center, Ministry of Health, Anxiety and Stress Research Unit, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
| |
Collapse
|
7
|
Carmi L, Brakoulias V, Arush OB, Cohen H, Zohar J. A prospective clinical cohort-based study of the prevalence of OCD, obsessive compulsive and related disorders, and tics in families of patients with OCD. BMC Psychiatry 2022; 22:190. [PMID: 35300642 PMCID: PMC8932237 DOI: 10.1186/s12888-022-03807-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/30/2021] [Accepted: 02/23/2022] [Indexed: 11/26/2022] Open
Abstract
BACKGROUND The lifetime prevalence of obsessive - compulsive disorder (OCD) is currently estimated at 2 - 3% and the prevalence in first-degree family members is estimated to range between 10 and 11%. Separating OCD from other anxiety disorders and including it into the new "obsessive - compulsive and related disorders" (OCRDs) category has had a dramatic impact on the diagnosis, while also contributing to the better understanding of the genetics of these disorders. Indeed, grouping OCD with body dysmorphic disorder (BDD), and body-focused repetitive behaviors such as trichotillomania (hair pulling), onychophagia (nail biting), and excoriation (skin picking) into the same diagnostic family has resulted in a much greater lifetime prevalence (> 9%). These diagnostic changes necessitate an updated epidemiological study, thus motivating this investigation. METHODS The study sample comprised of 457 patient's cases from an Israeli and an Australian OCD center. Interviews were completed as a part of the intake or during treatment in each of the centers. Prevalence of OCD, OCRDs, tics, and other psychiatric comorbidities in first- and second-degree relatives was assessed by interviewing the OCD patients. Interviews were conducted by at least two researchers (LC, OBA, JZ) and only family information on which the interviewers have reached consensus was considered. RESULTS Initial analyses revealed an increase of OCD and OCRD prevalence in first- and second-degree family members as compared to the current literature due to reclassification of these disorders in DSM-5. CONCLUSION The new category of OCRD has changed the landscape of epidemiological studies in OCD. Further and broader studies are needed in order to better understand the lifetime prevalence of OCRD in first- and second-degrees family member.
Collapse
Affiliation(s)
- Lior Carmi
- grid.413795.d0000 0001 2107 2845Chaim Sheba Medical Center, Post Trauma Center, Ramat-Gan, Israel ,Israeli Center for the Treatment of Obsessive−Compulsive and Related Disorders, Modiin, Israel
| | - Vlasios Brakoulias
- grid.482212.f0000 0004 0495 2383Western Sydney Obsessive−Compulsive and Related Disorders Service, Western Sydney Local Health District – Mental Health Services, North Parramatta, Australia ,grid.1029.a0000 0000 9939 5719School of Medicine and Translational Health Research Institute, Western Sydney University, Sydney, Australia
| | - Oded Ben Arush
- Israeli Center for the Treatment of Obsessive−Compulsive and Related Disorders, Modiin, Israel
| | - Hagit Cohen
- grid.7489.20000 0004 1937 0511Ministry of Health, Anxiety and Stress Research Unit, Faculty of Health Sciences, Beer-Sheva Mental Health Center, Ben-Gurion University of the Negev, Be’er Sheva, Israel
| | - Joseph Zohar
- Chaim Sheba Medical Center, Post Trauma Center, Ramat-Gan, Israel. .,Israeli Center for the Treatment of Obsessive-Compulsive and Related Disorders, Modiin, Israel.
| |
Collapse
|
8
|
Carmi L, Tendler A, Bystritsky A, Hollander E, Blumberger DM, Daskalakis J, Ward H, Lapidus K, Goodman W, Casuto L, Feifel D, Barnea-Ygael N, Roth Y, Zangen A, Zohar J. Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial. Focus (Am Psychiatr Publ) 2022; 20:152-159. [PMID: 35746941 PMCID: PMC9063595 DOI: 10.1176/appi.focus.20103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/16/2018] [Revised: 02/18/2019] [Accepted: 03/12/2019] [Indexed: 01/03/2023]
Abstract
(Appeared originally in American Journal of Psychiatry 2019; 176:931-938) Reprinted with permission from American Psychiatric Association Publishing.
Collapse
|
9
|
Pallanti S, Marras A, Dickson SL, Adan RA, Vieta E, Dell Osso B, Arango C, Fusar-Poli P, Soriano-Mas C, Carmi L, Meyer Lindenberg A, Zohar J. Manifesto for an ECNP Neuromodulation Thematic Working Group (TWG): Non-invasive brain stimulation as a new Super-subspecialty. Eur Neuropsychopharmacol 2021; 52:72-83. [PMID: 34348181 DOI: 10.1016/j.euroneuro.2021.07.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/14/2020] [Revised: 07/03/2021] [Accepted: 07/06/2021] [Indexed: 10/20/2022]
Abstract
Non-Invasive Brain Stimulation (NIBS) techniques and in particular, repetitive Transcranial Magnetic Stimulation (rTMS), are developing beyond mere clinical application. Although originally purposed for the treatment of resistant neuropsychiatric disorders, NIBS is also contributing to a deeper understanding of psychiatric disorders. rTMS is also changing the model of the disorder itself, from "mental" to one of neural connectivity. TMS allows the assessment of brain circuit excitability and eventually, of plastic changes affecting these circuits. While a clinical translational approach is, at the present time, the most adequate to meet the dimensional-circuit base model of the disorder, it refines the standard categorical classification of psychiatric disorders. The discovery of the fundamental importance of the balance between neuroplasticity and inflammation is also now explored through neuro-modulation findings consistently with the evidence of anti-inflammatory actions of the magnetic pulses. rTMS may activate, inhibit, or otherwise interfere with the activity of neuronal cortical networks, depending on stimulus frequency and intensity of brain-induced electric field. Of particular interest, yet still unclear, is how the relatively unspecific nature of TMS stimulation may lead to specific neuronal reorganization, as well as a definition of the TMS-triggered reorganization of functional brain modules, raising attention on the importance of the active participation of the patient to the treatment.. Configuration and state of consciousness of the subject have made subjective experience under treatment regain importance in the neuro-scientific Psychiatry based on the requirement of United States National Institute of Health (NIH) and the substantial importance of the consciousness state in the efficacy of the TMS treatment. By focusing on the subjective experience, a renaissance of the phenomenology offers Psychiatry an opportunity to become proficient and to distinguish itself from other disciplines. For all these reasons, TMS should be included in the cluster of the sub-specialties as a new "Super-Specialty" and an appropriate training course has to be inaugurated. Psychiatrists are nowadays multi-specialists, moving from a specialty to another, vs super-specialist. The cultivation of a properly trained cohort of TMS psychiatrists will better meet the challenges of treatment-resistant psychiatric conditions (disorders of connectivity), through appropriate and ethical practice, meanwhile facilitating an informed development and integration of additional emerging neuro-modulation techniques. The aim of this consensus paper is to underline the interdisciplinary nature of NIBS, that also encompasses the subjective experience and to point out the necessity of a neuroscience-applied approach to NIBS in the context of the European College of Neuro-psychopharmacology (ECNP).
Collapse
Affiliation(s)
- Stefano Pallanti
- Istituto di Neuroscienze, Florence, IT; Albert Einstein College of Medicine and Montefiore Medical Center, NY, USA.
| | - Anna Marras
- Istituto di Neuroscienze, Florence, IT; Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Florence, IT
| | - Suzanne L Dickson
- Department of Physiology/Endocrine, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Sweden
| | - Roger Ah Adan
- Department of Translational Neuroscience, UMCU Brain Center, University Medical Center Utrecht, Utrecht University, The Netherlands; Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Sweden
| | - Eduard Vieta
- Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - Bernardo Dell Osso
- Ospedale Sacco-Polo Universitario, Psychiatric Clinic, Milano; University of Milano, IT
| | - Celso Arango
- Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IiSGM, CIBERSAM, Madrid 28009, Spain
| | - Paolo Fusar-Poli
- Early Psychosis: Interventions and Clinical-detection (EPIC) lab, Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan. Aldo Ravelli' Research Center for Neurotechnology and Experimental Brain Therapeutics, Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK; Department of Health Sciences, University of Milan, Milan, Italy; Department of Psychiatry and Brain and Behavioral Sciences, Stanford University, California, USA. of Pavia, Pavia, Italy
| | - Carles Soriano-Mas
- Bellvitge Biomedical Research Institute-IDIBELL, Psychiatry Service, Bellvitge University Hospital and CIBERSAM,Barcelona, Spain. Department of Psychobiology and Methodology in Health Sciences, Universitat Autònoma de Barcelona, Spain
| | - Lior Carmi
- Academic Laboratory Manager, The National Institute of PTSD, Chaim Sheba Medical Center, School Of Psychological sciences, Tel Aviv University, Israel
| | - Andreas Meyer Lindenberg
- Central Institute of Mental Health, Mannheim; Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Chair of Psychiatry and Psychotherapy, University of Heidelberg, Germany
| | - Joseph Zohar
- Sheba Medical Center at Tel Hashomer, Israel, Sackler Faculty of Medicine, Tel Aviv
| |
Collapse
|
10
|
Castro‐Calvo J, King DL, Stein DJ, Brand M, Carmi L, Chamberlain SR, Demetrovics Z, Fineberg NA, Rumpf H, Yücel M, Achab S, Ambekar A, Bahar N, Blaszczynski A, Bowden‐Jones H, Carbonell X, Chan EML, Ko C, de Timary P, Dufour M, Grall‐Bronnec M, Lee HK, Higuchi S, Jimenez‐Murcia S, Király O, Kuss DJ, Long J, Müller A, Pallanti S, Potenza MN, Rahimi‐Movaghar A, Saunders JB, Schimmenti A, Lee S, Siste K, Spritzer DT, Starcevic V, Weinstein AM, Wölfling K, Billieux J. Expert appraisal of criteria for assessing gaming disorder: an international Delphi study. Addiction 2021; 116:2463-2475. [PMID: 33449441 PMCID: PMC8451754 DOI: 10.1111/add.15411] [Citation(s) in RCA: 91] [Impact Index Per Article: 30.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/26/2020] [Revised: 09/23/2020] [Accepted: 01/06/2021] [Indexed: 12/15/2022]
Abstract
BACKGROUND AND AIMS Following the recognition of 'internet gaming disorder' (IGD) as a condition requiring further study by the DSM-5, 'gaming disorder' (GD) was officially included as a diagnostic entity by the World Health Organization (WHO) in the 11th revision of the International Classification of Diseases (ICD-11). However, the proposed diagnostic criteria for gaming disorder remain the subject of debate, and there has been no systematic attempt to integrate the views of different groups of experts. To achieve a more systematic agreement on this new disorder, this study employed the Delphi expert consensus method to obtain expert agreement on the diagnostic validity, clinical utility and prognostic value of the DSM-5 criteria and ICD-11 clinical guidelines for GD. METHODS A total of 29 international experts with clinical and/or research experience in GD completed three iterative rounds of a Delphi survey. Experts rated proposed criteria in progressive rounds until a pre-determined level of agreement was achieved. RESULTS For DSM-5 IGD criteria, there was an agreement both that a subset had high diagnostic validity, clinical utility and prognostic value and that some (e.g. tolerance, deception) had low diagnostic validity, clinical utility and prognostic value. Crucially, some DSM-5 criteria (e.g. escapism/mood regulation, tolerance) were regarded as incapable of distinguishing between problematic and non-problematic gaming. In contrast, ICD-11 diagnostic guidelines for GD (except for the criterion relating to diminished non-gaming interests) were judged as presenting high diagnostic validity, clinical utility and prognostic value. CONCLUSIONS This Delphi survey provides a foundation for identifying the most diagnostically valid and clinically useful criteria for GD. There was expert agreement that some DSM-5 criteria were not clinically relevant and may pathologize non-problematic patterns of gaming, whereas ICD-11 diagnostic guidelines are likely to diagnose GD adequately and avoid pathologizing.
Collapse
Affiliation(s)
- Jesús Castro‐Calvo
- Department of Personality, Assessment, and Psychological TreatmentsUniversity of ValenciaSpain
| | - Daniel L. King
- College of Education, Psychology, and Social WorkFlinders UniversityAustralia
| | - Dan J. Stein
- SAMRC Unit on Risk and Resilience in Mental Disorders, Department of Psychiatry and Neuroscience InstituteUniversity of Cape TownCape TownSouth Africa
| | - Matthias Brand
- General Psychology: Cognition and Center for Behavioral Addiction Research (CeBAR)University Duisburg‐EssenGermany
| | - Lior Carmi
- The Data Science InstituteInter‐disciplinary CenterHerzliyaIsrael
| | - Samuel R. Chamberlain
- Department of Psychiatry, Faculty of MedicineUniversity of SouthamptonSouthamptonUK,Southern Health NHS Foundation TrustSouthamptonUK
| | | | - Naomi A. Fineberg
- University of Hertfordshire, Hatfield, UK, Hertfordshire Partnership University NHS Foundation TrustWelwyn Garden CityUK,University of Cambridge School of Clinical MedicineCambridgeUK
| | - Hans‐Jürgen Rumpf
- Department of Psychiatry and PsychotherapyUniversity of LuebeckLuebeckGermany
| | - Murat Yücel
- BrainPark, School of Psychological Sciences, Turner Institute for Brain and Mental Health and Monash Biomedical Imaging FacilityMonash UniversityMelbourneVictoriaAustralia
| | - Sophia Achab
- Specialized Facility In Behavioral Addictions, ReConnecte, Department of PsychiatryUniversity Hospitals of GenevaGenervaSwitzerland,Faculty of MedicineGeneva UniversityGenevaSwitzerland
| | - Atul Ambekar
- National Drug Dependence Treatment CentreAll India Institute of Medical SciencesNew DelhiIndia
| | - Norharlina Bahar
- Department of Psychiatry and Mental Health, Hospital Selayang, Ministry of HealthMalaysia
| | - Alexander Blaszczynski
- Faculty of Science, Brain and Mind Centre, School of PsychologyUniversity of SydneySydneyAustralia
| | | | - Xavier Carbonell
- Faculty of Psychology, Education and Sports Sciences BlanquernaRamon Llull UniversityBarcelonaSpain
| | - Elda Mei Lo Chan
- St John's Cathedral Counselling Service, and Division on AddictionHong Kong
| | - Chih‐Hung Ko
- Department of PsychiatryKaohsiung Medical University Hospital, Kaohsiung Medical UniversityKaohsiung CityTaiwan
| | - Philippe de Timary
- Department of Adult PsychiatryInstitute of Neuroscience, UCLouvain and Cliniques Universitaires Saint‐LucBrusselsBelgium
| | | | - Marie Grall‐Bronnec
- CHU Nantes, Department of Addictology and PsychiatryNantesFrance,Universités de Nantes et Tours, UMR 1246NantesFrance
| | - Hae Kook Lee
- Department of Psychiatry, College of MedicineThe Catholic University of KoreaSeoulSouth Korea
| | - Susumu Higuchi
- National Hospital OrganizationKurihama Medical and Addiction CenterJapan
| | - Susana Jimenez‐Murcia
- Department of PsychiatryBellvitge University Hospital‐IDIBELLBarcelonaSpain,Ciber Fisiopatología Obesidad y Nutrición (CIBERObn)Instituto de Salud Carlos IIIMadridSpain
| | - Orsolya Király
- Institute of PsychologyELTE Eötvös Loránd UniversityBudapestHungary
| | - Daria J. Kuss
- International Gaming Research Unit, Psychology DepartmentNottingham Trent UniversityNottinghamUK
| | - Jiang Long
- Shanghai Mental Health CenterShanghai Jiao Tong University School of MedicineShanghaiChina,Laboratory for Experimental Psychopathology, Psychological Science Research InstituteUniversité Catholique de LouvainLouvainBelgium
| | - Astrid Müller
- Department of Psychosomatic Medicine and PsychotherapyHannover Medical SchoolHanoverGermany
| | | | - Marc N. Potenza
- Departments of Psychiatry and Neuroscience and the Child Study CenterYale School of Medicine and Connecticut Mental Health CenterNew HavenCTUSA
| | - Afarin Rahimi‐Movaghar
- Iranian National Center for Addiction StudiesTehran University of Medical SciencesTehranIran
| | - John B. Saunders
- Centre for Youth Substance Abuse ResearchUniversity of QueenslandBrisbaneQueenslandAustralia
| | | | - Seung‐Yup Lee
- Department of Psychiatry, Eunpyeong St Mary's Hospital, College of MedicineThe Catholic University of KoreaSeoulSouth Korea
| | - Kristiana Siste
- Department of Psychiatry, Faculty of Medicine, Universitas IndonesiaJakartaIndonesia,Cipto Mangunkusumo HospitalJakartaIndonesia
| | - Daniel T. Spritzer
- Postgraduate Program in Psychiatry and Behavioral SciencesFederal University of Rio Grande do SulBrazil
| | - Vladan Starcevic
- Faculty of Medicine and Health, Sydney Medical School, Nepean Clinical SchoolUniversity of SydneySydneyAustralia
| | | | - Klaus Wölfling
- Outpatient Clinic for Behavioral Addictions, Department of Psychosomatic Medicine and PsychotherapyUniversity Medical Center of the Johannes Gutenberg‐University MainzGermany
| | - Joël Billieux
- Institute of PsychologyUniversity of LausanneLausanneSwitzerland,Health and Behaviour InstituteUniversity of LuxembourgEsch‐sur‐AlzetteLuxembourg
| |
Collapse
|
11
|
Carmi L, Ben-Arush O, Fostick L, Cohen H, Zohar J. Obsessive Compulsive Disorder During Coronavirus Disease 2019 (COVID-19): 2- and 6-Month Follow-Ups in a Clinical Trial. Int J Neuropsychopharmacol 2021; 24:703-709. [PMID: 34048557 PMCID: PMC8195092 DOI: 10.1093/ijnp/pyab024] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/27/2020] [Revised: 04/18/2021] [Accepted: 05/26/2021] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND Psychiatric patients are perceived to be especially vulnerable during a pandemic, as it increases stress and uncertainty. Several current publications have considered obsessive-compulsive disorder (OCD) patients to be particularly vulnerable during the coronavirus disease 2019 (COVID-19), and clinicians were advised to adjust treatments accordingly. The purpose of this study was to evaluate the 2- and 6-month impacts of COVID-19 on the symptom severity of OCD patients. METHODS A cohort of OCD patients actively treated with Exposure and Response Prevention (ERP) combined with pharmacological treatment was evaluated as part of their regular psychiatric assessment twice: 113 patients were evaluated at their 2-month follow-up and 90 patients (from that cohort) were evaluated at their 6-month follow up. RESULTS Obsessive-compulsive symptom deterioration was not present in 84% of the patients at the 2-month follow-up and 96% of the patients at the 6-month follow-up. The results were also replicated in the OCD subgroup that included patients with contamination (washers) and illness obsessions, who were believed to be particularly vulnerable considering their obsessional content. CONCLUSIONS OCD patients (including those with obsessions related to contamination and health) who were under active ERP and pharmacological treatment did not experience exacerbated symptoms during COVID-19 at their 2- and 6-month follow-ups.
Collapse
Affiliation(s)
- Lior Carmi
- The Post-Trauma Center, Chaim Sheba Medical Center, Israel,The Israeli Center for OCD, Modiin, Israel,The Data Science Institution, The Interdisciplinary Center, Herzliya, Israel
| | | | - Leah Fostick
- Department of Communication Disorders, Ariel University, Israel
| | - Hagit Cohen
- Anxiety and Stress Research Unit, Beer-Sheva Mental Health Center, Faculty of Health Sciences, Division of Psychiatry, Ben-Gurion University of the Negev, Israel
| | - Joseph Zohar
- The Post-Trauma Center, Chaim Sheba Medical Center, Israel,The Israeli Center for OCD, Modiin, Israel,Correspondence: Joseph Zohar, MD, Chaim Sheba Medical Center, 2 Sheba Road St, 5262000 Israel ()
| |
Collapse
|
12
|
Roth Y, Barnea-Ygael N, Carmi L, Storch EA, Tendler A, Zangen A. Deep transcranial magnetic stimulation for obsessive-compulsive disorder is efficacious even in patients who failed multiple medications and CBT. Psychiatry Res 2020; 290:113179. [PMID: 32540588 DOI: 10.1016/j.psychres.2020.113179] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/07/2020] [Revised: 06/01/2020] [Accepted: 06/01/2020] [Indexed: 12/14/2022]
Abstract
OCD is a chronic and disabling disease with a lifetime prevalence of 2%-3%. About 40-60% of these patients do not adequately respond to pharmacotherapy and CBT. Deep transcranial magnetic stimulation (dTMS) was shown to be safe and effective as a treatment alternative for OCD and recently received regulatory approvals. Yet it is unclear whether patients who failed numerous medications and/or CBT can still benefit from dTMS. Here, we analyzed recent data from a double-blind multicenter dTMS study and found efficacy of this novel treatment even in OCD patient cohorts who previously failed to respond to multiple medications and CBT.
Collapse
Affiliation(s)
- Yiftach Roth
- The Department of Life Sciences and the Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva, Israel
| | - Noam Barnea-Ygael
- The Department of Life Sciences and the Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva, Israel
| | - Lior Carmi
- Chaim Sheba Medical Center, Ramat Gan, Israel
| | - Eric A Storch
- Department of Psychiatry & Behavioral Sciences, Baylor College of Medicine, TX, USA
| | - Aron Tendler
- Advanced Mental Health Care, Inc., Palm Beach, FL, USA
| | - Abraham Zangen
- The Department of Life Sciences and the Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
| |
Collapse
|
13
|
Fineberg N, Van Ameringen M, Drummond L, Hollander E, Stein D, Geller D, Walitza S, Pallanti S, Pellegrini L, Zohar J, Rodriguez C, Menchon J, Morgado P, Mpavaenda D, Fontenelle L, Feusner J, Grassi G, Lochner C, Veltman D, Sireau N, Carmi L, Adam D, Nicolini H, Dell'Osso B. How to manage obsessive-compulsive disorder (OCD) under COVID-19: A clinician's guide from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS) and the Obsessive-Compulsive and Related Disorders Research Network (OCRN) of the European College of Neuropsychopharmacology. Compr Psychiatry 2020; 100:152174. [PMID: 32388123 PMCID: PMC7152877 DOI: 10.1016/j.comppsych.2020.152174] [Citation(s) in RCA: 106] [Impact Index Per Article: 26.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/02/2020] [Revised: 04/07/2020] [Accepted: 04/07/2020] [Indexed: 12/19/2022] Open
Affiliation(s)
- N.A. Fineberg
- University of Hertfordshire, Hatfield, UK,Hertfordshire Partnership University NHS Foundation Trust, Welwyn Garden City, Hertfordshire, UK,University of Cambridge School of Clinical Medicine, Cambridge, UK,Corresponding author at: University of Hertfordshire, Hatfield, UK.
| | - M. Van Ameringen
- Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada,Hamilton Health Sciences, Hamilton, Ontario, Canada
| | - L. Drummond
- SW London and St George's NHS Trust and St George's, University of London, UK
| | - E. Hollander
- Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA
| | - D.J. Stein
- SA MRC Unit on Risk & Resilience in Mental Disorders, Dept of Psychiatry & Neuroscience Institute, University of Cape Town, Cape Town, South Africa
| | - D. Geller
- Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, USA
| | - S. Walitza
- Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich, Switzerland,Neuroscience Center Zurich, University of Zurich and ETH Zurich, Switzerland,Zurich Center for Integrative Human Physiology, University of Zurich, Switzerland
| | - S. Pallanti
- Istituto di Neuroscienze, University of Florence, Italy,Albert Einstein College of Medicine, New York, USA
| | - L. Pellegrini
- University of Hertfordshire, Hatfield, UK,Hertfordshire Partnership University NHS Foundation Trust, Welwyn Garden City, Hertfordshire, UK,Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy
| | - J. Zohar
- The Post Trauma Center, Chaim Sheba Medical Center, Israel,Tel Aviv University, Israel
| | - C.I. Rodriguez
- Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA,Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA
| | - J.M. Menchon
- Department of Psychiatry, Bellvitge University Hospital-IDIBELL, University of Barcelona, Cibersam, Barcelona, Spain
| | - P. Morgado
- Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal,ICVS-3Bs PT Government Associate Laboratory, Braga/Guimarães, Portugal,Clinical Academic Center – Braga, Hospital de Braga, Braga, Portugal
| | - D. Mpavaenda
- University of Hertfordshire, Hatfield, UK,Hertfordshire Partnership University NHS Foundation Trust, Welwyn Garden City, Hertfordshire, UK
| | - L.F. Fontenelle
- Turner Institute for Brain and Mental Health, Monash University, Victoria, Australia,D'Or Institute for Research and Education and Institute of Psychiatry, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
| | - J.D. Feusner
- Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, USA
| | - G. Grassi
- Brain Center Firenze, Florence, Italy
| | - C. Lochner
- SA MRC Unit on Risk and Resilience in Mental Disorders, Department of Psychiatry, University of Stellenbosch, South Africa
| | - D.J. Veltman
- Department of Psychiatry, Amsterdam UMC location VUMC, Amsterdam, the Netherlands
| | - N. Sireau
- Orchard, 66 Devonshire Road, Cambridge CB1 2BL, UK
| | - L. Carmi
- The Post Trauma Center, Chaim Sheba Medical Center, Israel
| | | | - H. Nicolini
- Genomics of Psychiatric and Neurodegenerative Diseases Laboratory, National Institute of Genomic Medicine (INMEGEN), Mexico City, Mexico,Clinical Research, Carracci Medical Group, Mexico City, Mexico
| | - B. Dell'Osso
- University of Milan, Department of Biomedical and Clinical Sciences, Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy,“Aldo Ravelli” Center for Neurotechnology and Brain Therapeutic, University of Milan, Milan, Italy
| |
Collapse
|
14
|
Fineberg NA, Hollander E, Pallanti S, Walitza S, Grünblatt E, Dell’Osso BM, Albert U, Geller DA, Brakoulias V, Janardhan Reddy Y, Arumugham SS, Shavitt RG, Drummond L, Grancini B, De Carlo V, Cinosi E, Chamberlain SR, Ioannidis K, Rodriguez CI, Garg K, Castle D, Van Ameringen M, Stein DJ, Carmi L, Zohar J, Menchon JM. Clinical advances in obsessive-compulsive disorder: a position statement by the International College of Obsessive-Compulsive Spectrum Disorders. Int Clin Psychopharmacol 2020; 35:173-193. [PMID: 32433254 PMCID: PMC7255490 DOI: 10.1097/yic.0000000000000314] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/27/2020] [Accepted: 03/16/2020] [Indexed: 11/25/2022]
Abstract
In this position statement, developed by The International College of Obsessive-Compulsive Spectrum Disorders, a group of international experts responds to recent developments in the evidence-based management of obsessive-compulsive disorder (OCD). The article presents those selected therapeutic advances judged to be of utmost relevance to the treatment of OCD, based on new and emerging evidence from clinical and translational science. Areas covered include refinement in the methods of clinical assessment, the importance of early intervention based on new staging models and the need to provide sustained well-being involving effective relapse prevention. The relative benefits of psychological, pharmacological and somatic treatments are reviewed and novel treatment strategies for difficult to treat OCD, including neurostimulation, as well as new areas for research such as problematic internet use, novel digital interventions, immunological therapies, pharmacogenetics and novel forms of psychotherapy are discussed.
Collapse
Affiliation(s)
- Naomi A. Fineberg
- University of Hertfordshire, Hatfield
- Hertfordshire Partnership University NHS Foundation Trust, Welwyn Garden City, Hertfordshire
- University of Cambridge School of Clinical Medicine, Cambridge, UK
| | - Eric Hollander
- Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA
| | - Stefano Pallanti
- Istituto di Neuroscienze, University of Florence, Firenze, Italy
- Albert Einstein College of Medicine, Bronx, New York, USA
| | - Susanne Walitza
- Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich
- Neuroscience Center Zurich, University of Zurich and ETH Zurich
- Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland
| | - Edna Grünblatt
- Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich
- Neuroscience Center Zurich, University of Zurich and ETH Zurich
- Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland
| | - Bernardo Maria Dell’Osso
- University of Milan, Department of Biomedical and Clinical Sciences Luigi Sacco, Ospedale Sacco-Polo Universitario, ASST Fatebenefratelli-Sacco, Milan, Italy
- Department of Psychiatry and Behavioural Sciences, Stanford University, California, USA
- CRC ‘Aldo Ravelli’ for Neurotechnology and Experimental Brain Therapeutics, University of Milan, Milan
- Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford
| | - Umberto Albert
- Department of Medicine, Surgery and Health Sciences, UCO Clinica Psichiatrica, University of Trieste, Trieste, Italy
| | - Daniel A. Geller
- Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Vlasios Brakoulias
- Western Sydney Obsessive-Compulsive and Related Disorders Service, Western Sydney Local Health District, Blacktown Hospital, Blacktown, New South Wales
- Translational Research Health Institute (THRI), Clinical and Health Psychology Research Initiative (CaHPRI) and School of Medicine, Western Sydney University, Sydney, Australia
| | - Y.C. Janardhan Reddy
- OCD Clinic, Department of Psychiatry, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bengaluru, India
| | - Shyam Sundar Arumugham
- OCD Clinic, Department of Psychiatry, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bengaluru, India
| | - Roseli G. Shavitt
- OCD Spectrum Disorders Program, Institute and Department of Psychiatry, Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo-SP, Brazil
| | - Lynne Drummond
- Consultant Psychiatrist, SW London and St George’s NHS Trust and St George’s, University of London, London
| | - Benedetta Grancini
- Hertfordshire Partnership University NHS Foundation Trust, Welwyn Garden City, Hertfordshire
- University of Milan, Department of Biomedical and Clinical Sciences Luigi Sacco, Ospedale Sacco-Polo Universitario, ASST Fatebenefratelli-Sacco, Milan, Italy
| | - Vera De Carlo
- Hertfordshire Partnership University NHS Foundation Trust, Welwyn Garden City, Hertfordshire
- University of Milan, Department of Biomedical and Clinical Sciences Luigi Sacco, Ospedale Sacco-Polo Universitario, ASST Fatebenefratelli-Sacco, Milan, Italy
| | - Eduardo Cinosi
- University of Hertfordshire, Hatfield
- Hertfordshire Partnership University NHS Foundation Trust, Welwyn Garden City, Hertfordshire
| | - Samuel R. Chamberlain
- Department of Psychiatry, University of Cambridge, Cambridge
- Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK
| | - Konstantinos Ioannidis
- Department of Psychiatry, University of Cambridge, Cambridge
- Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK
| | - Carolyn I. Rodriguez
- Department of Psychiatry and Behavioural Sciences, Stanford University, California, USA
- Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA
| | - Kabir Garg
- Hertfordshire Partnership University NHS Foundation Trust, Welwyn Garden City, Hertfordshire
| | - David Castle
- St. Vincent’s Hospital Melbourne and The University of Melbourne, Melbourne, Australia
| | - Michael Van Ameringen
- Department of Psychiatry and Behavioural Neurosciences, McMaster University
- Hamilton Health Sciences, Hamilton, Ontario, Canada
| | - Dan J. Stein
- SA MRC Unit on Risk and Resilience in Mental Disorders, Department of Psychiatry and Neuroscience Institute, University of Cape Town, Cape Town, South Africa
| | - Lior Carmi
- The Post Trauma Center, Chaim Sheba Medical Center, Ramat Gan
- The Data Science Institution, The Interdisciplinary Center, Herzliya
| | - Joseph Zohar
- The Post Trauma Center, Chaim Sheba Medical Center, Ramat Gan
- Tel Aviv University, Tel Aviv-Yafo, Israel
| | - Jose M. Menchon
- Department of Psychiatry, Bellvitge University Hospital-IDIBELL, University of Barcelona, Cibersam, Barcelona, Spain
| |
Collapse
|
15
|
Cohen H, Zohar J, Carmi L. Effects of agomelatine on behaviour, circadian expression of period 1 and period 2 clock genes and neuroplastic markers in the predator scent stress rat model of PTSD. World J Biol Psychiatry 2020; 21:255-273. [PMID: 30230406 DOI: 10.1080/15622975.2018.1523560] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Objectives: The therapeutic value of the antidepressant agomelatine in the aftermath of traumatic experience and early post-reminder has been questioned. Herein, agomelatine, its vehicle or melatonin agonist were administered either acutely 1 h post-stressor or repeatedly (7 days) after early post-reminder in a post-traumatic stress rat model (PSS) using the scent of predator urine.Methods: Behavioural responses, and brain molecular and morphological changes were evaluated after each treatment procedure in PSS-exposed and unexposed rats.Results: When administered immediately after PSS, agomelatine induced a significant reduction of anxiety-like behaviour as assessed in the elevated-plus-maze and acoustic startle response at 8 days post-administration. Concomitantly, agomelatine significantly decreased Per1/Per2 expression in the CA1/CA3 areas, suprachiasmatic nucleus and basolateral amygdala, thereby partially restoring genes expression overregulated by PSS. Agomelatine further significantly increased cell growth and facilitated dendritic growth and arbour in dentate gyrus (DG) granule and apical CA1 cells and upregulated brain-derived neurotrophic factor protein in the DG and cortex III versus vehicle. When administered early post-reminder over 7 days before testing, agomelatine was ineffective on behavioural responses pattern, molecular and morphological changes induced by PSS.Conclusions: These findings suggest that agomelatine may be a potential agent in the acute aftermath of traumatic stress exposure.
Collapse
Affiliation(s)
- Hagit Cohen
- Beer-Sheva Mental Health Center, The State of Israel Ministry of Health, Anxiety and Stress Research Unit, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beersheba, Israel
| | - Joseph Zohar
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Lior Carmi
- School of Psychological Sciences, Tel Aviv University, Tel Aviv, Israel
| |
Collapse
|
16
|
Vermetten E, Granek J, Boland H, Berge ET, Binsch O, Carmi L, Zohar J, Wynn G, Jetly R. Leveraging technology to improve military mental health: Novel uses of smartphone apps. Journal of Military, Veteran and Family Health 2020. [DOI: 10.3138/jmvfh.2019-0034] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Introduction: Smartphones have made promising contributions to the field of military mental health by providing novel app-based approaches to enhance training and deployment, data collection, and creating social domains for participants to share information and perform research. Methods: This article reviews four applications designed specifically for military members and Veterans that increase mental health literacy, overcome barriers to care, and enhance well-being and performance. Results: The Road to Mental Readiness (R2MR) app is an on-the-go training tool based on cognitive behavioural theory (CBT). Unit Victor connects Veterans in a secure chat environment and provides information on available supports. UrMMIND is a pre-deployment tool designed to reinforce healthy behaviours and teach coping techniques. iFeel passively collects and analyses individual smartphone data to detect early signs of depression. Discussion: Mobile apps are playing an ever-increasing role within health care and, when designed and integrated correctly, can yield many benefits. While security and privacy need to be carefully weighed and addressed, they hold the potential to empower the end user in a range of novel ways that were not possible before.
Collapse
Affiliation(s)
- Eric Vermetten
- Military Mental Health Research, Ministry of Defense, Utrecht, the Netherlands
- Leiden University Medical Center, Leiden, the Netherlands
- ARQ National Psychotrauma Center, Diemen, the Netherlands
- Defence Research and Development Canada, Toronto Research Centre, Toronto
- No Worries Company, the Netherlands
| | - Josh Granek
- Military Mental Health Research, Ministry of Defense, Utrecht, the Netherlands
- Leiden University Medical Center, Leiden, the Netherlands
- ARQ National Psychotrauma Center, Diemen, the Netherlands
- Defence Research and Development Canada, Toronto Research Centre, Toronto
- No Worries Company, the Netherlands
| | - Hamid Boland
- Military Mental Health Research, Ministry of Defense, Utrecht, the Netherlands
- Leiden University Medical Center, Leiden, the Netherlands
- ARQ National Psychotrauma Center, Diemen, the Netherlands
- Defence Research and Development Canada, Toronto Research Centre, Toronto
- No Worries Company, the Netherlands
| | - Erik ten Berge
- Military Mental Health Research, Ministry of Defense, Utrecht, the Netherlands
- Leiden University Medical Center, Leiden, the Netherlands
- ARQ National Psychotrauma Center, Diemen, the Netherlands
- Defence Research and Development Canada, Toronto Research Centre, Toronto
- No Worries Company, the Netherlands
| | - Olaf Binsch
- Military Mental Health Research, Ministry of Defense, Utrecht, the Netherlands
- Leiden University Medical Center, Leiden, the Netherlands
- ARQ National Psychotrauma Center, Diemen, the Netherlands
- Defence Research and Development Canada, Toronto Research Centre, Toronto
- No Worries Company, the Netherlands
| | - Lior Carmi
- Military Mental Health Research, Ministry of Defense, Utrecht, the Netherlands
- Leiden University Medical Center, Leiden, the Netherlands
- ARQ National Psychotrauma Center, Diemen, the Netherlands
- Defence Research and Development Canada, Toronto Research Centre, Toronto
- No Worries Company, the Netherlands
| | - Joseph Zohar
- Military Mental Health Research, Ministry of Defense, Utrecht, the Netherlands
- Leiden University Medical Center, Leiden, the Netherlands
- ARQ National Psychotrauma Center, Diemen, the Netherlands
- Defence Research and Development Canada, Toronto Research Centre, Toronto
- No Worries Company, the Netherlands
| | - Gary Wynn
- Military Mental Health Research, Ministry of Defense, Utrecht, the Netherlands
- Leiden University Medical Center, Leiden, the Netherlands
- ARQ National Psychotrauma Center, Diemen, the Netherlands
- Defence Research and Development Canada, Toronto Research Centre, Toronto
- No Worries Company, the Netherlands
| | - Rakesh Jetly
- Military Mental Health Research, Ministry of Defense, Utrecht, the Netherlands
- Leiden University Medical Center, Leiden, the Netherlands
- ARQ National Psychotrauma Center, Diemen, the Netherlands
- Defence Research and Development Canada, Toronto Research Centre, Toronto
- No Worries Company, the Netherlands
| |
Collapse
|
17
|
Carmi L, Tendler A, Bystritsky A, Hollander E, Blumberger DM, Daskalakis J, Ward H, Lapidus K, Goodman W, Casuto L, Feifel D, Barnea-Ygael N, Roth Y, Zangen A, Zohar J. Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial. Am J Psychiatry 2019; 176:931-938. [PMID: 31109199 DOI: 10.1176/appi.ajp.2019.18101180] [Citation(s) in RCA: 212] [Impact Index Per Article: 42.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
OBJECTIVE Obsessive-compulsive disorder (OCD) is a chronic and disabling condition that often responds unsatisfactorily to pharmacological and psychological treatments. Converging evidence suggests a dysfunction of the cortical-striatal-thalamic-cortical circuit in OCD, and a previous feasibility study indicated beneficial effects of deep transcranial magnetic stimulation (dTMS) targeting the medial prefrontal cortex and the anterior cingulate cortex. The authors examined the therapeutic effect of dTMS in a multicenter double-blind sham-controlled study. METHODS At 11 centers, 99 OCD patients were randomly allocated to treatment with either high-frequency (20 Hz) or sham dTMS and received daily treatments following individualized symptom provocation, for 6 weeks. Clinical response to treatment was determined using the Yale-Brown Obsessive Compulsive Scale (YBOCS), and the primary efficacy endpoint was the change in score from baseline to posttreatment assessment. Additional measures were response rates (defined as a reduction of ≥30% in YBOCS score) at the posttreatment assessment and after another month of follow-up. RESULTS Eighty-nine percent of the active treatment group and 96% of the sham treatment group completed the study. The reduction in YBOCS score among patients who received active dTMS treatment was significantly greater than among patients who received sham treatment (reductions of 6.0 points and 3.3 points, respectively), with response rates of 38.1% and 11.1%, respectively. At the 1-month follow-up, the response rates were 45.2% in the active treatment group and 17.8% in the sham treatment group. Significant differences between the groups were maintained at follow-up. CONCLUSIONS High-frequency dTMS over the medial prefrontal cortex and anterior cingulate cortex significantly improved OCD symptoms and may be considered as a potential intervention for patients who do not respond adequately to pharmacological and psychological interventions.
Collapse
Affiliation(s)
- Lior Carmi
- The School of Psychological Science, Tel Aviv University, Tel Aviv, Israel (Carmi); the Department of Life Sciences and the Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva, Israel (Carmi, Barnea-Ygael, Roth, Zangen); Advanced Mental Health Care, Inc., Palm Beach, Fla. (Tendler); the Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles (Bystritsky); the Spectrum Neuroscience and Treatment Center, New York (Hollander); the Temerty Centre for Therapeutic Brain Intervention and the Campbell Family Research Institute, Centre for Addiction and Mental Health, and the Department of Psychiatry, University of Toronto, Ontario (Blumberger, Daskalakis); the Department of Psychiatry, University of Florida, Gainesville (Ward); the Department of Psychiatry, Northwell Health, New York (Lapidus); the Department of Psychiatry and Behavioral Health System, Icahn School of Medicine at Mount Sinai, New York (Goodman); the Lindner Center of HOPE, Mason, Ohio (Casuto); the Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati (Casuto); the Department of Psychiatry, University of California San Diego, La Jolla (Feifel); the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (Zohar)
| | - Aron Tendler
- The School of Psychological Science, Tel Aviv University, Tel Aviv, Israel (Carmi); the Department of Life Sciences and the Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva, Israel (Carmi, Barnea-Ygael, Roth, Zangen); Advanced Mental Health Care, Inc., Palm Beach, Fla. (Tendler); the Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles (Bystritsky); the Spectrum Neuroscience and Treatment Center, New York (Hollander); the Temerty Centre for Therapeutic Brain Intervention and the Campbell Family Research Institute, Centre for Addiction and Mental Health, and the Department of Psychiatry, University of Toronto, Ontario (Blumberger, Daskalakis); the Department of Psychiatry, University of Florida, Gainesville (Ward); the Department of Psychiatry, Northwell Health, New York (Lapidus); the Department of Psychiatry and Behavioral Health System, Icahn School of Medicine at Mount Sinai, New York (Goodman); the Lindner Center of HOPE, Mason, Ohio (Casuto); the Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati (Casuto); the Department of Psychiatry, University of California San Diego, La Jolla (Feifel); the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (Zohar)
| | - Alexander Bystritsky
- The School of Psychological Science, Tel Aviv University, Tel Aviv, Israel (Carmi); the Department of Life Sciences and the Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva, Israel (Carmi, Barnea-Ygael, Roth, Zangen); Advanced Mental Health Care, Inc., Palm Beach, Fla. (Tendler); the Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles (Bystritsky); the Spectrum Neuroscience and Treatment Center, New York (Hollander); the Temerty Centre for Therapeutic Brain Intervention and the Campbell Family Research Institute, Centre for Addiction and Mental Health, and the Department of Psychiatry, University of Toronto, Ontario (Blumberger, Daskalakis); the Department of Psychiatry, University of Florida, Gainesville (Ward); the Department of Psychiatry, Northwell Health, New York (Lapidus); the Department of Psychiatry and Behavioral Health System, Icahn School of Medicine at Mount Sinai, New York (Goodman); the Lindner Center of HOPE, Mason, Ohio (Casuto); the Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati (Casuto); the Department of Psychiatry, University of California San Diego, La Jolla (Feifel); the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (Zohar)
| | - Eric Hollander
- The School of Psychological Science, Tel Aviv University, Tel Aviv, Israel (Carmi); the Department of Life Sciences and the Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva, Israel (Carmi, Barnea-Ygael, Roth, Zangen); Advanced Mental Health Care, Inc., Palm Beach, Fla. (Tendler); the Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles (Bystritsky); the Spectrum Neuroscience and Treatment Center, New York (Hollander); the Temerty Centre for Therapeutic Brain Intervention and the Campbell Family Research Institute, Centre for Addiction and Mental Health, and the Department of Psychiatry, University of Toronto, Ontario (Blumberger, Daskalakis); the Department of Psychiatry, University of Florida, Gainesville (Ward); the Department of Psychiatry, Northwell Health, New York (Lapidus); the Department of Psychiatry and Behavioral Health System, Icahn School of Medicine at Mount Sinai, New York (Goodman); the Lindner Center of HOPE, Mason, Ohio (Casuto); the Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati (Casuto); the Department of Psychiatry, University of California San Diego, La Jolla (Feifel); the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (Zohar)
| | - Daniel M Blumberger
- The School of Psychological Science, Tel Aviv University, Tel Aviv, Israel (Carmi); the Department of Life Sciences and the Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva, Israel (Carmi, Barnea-Ygael, Roth, Zangen); Advanced Mental Health Care, Inc., Palm Beach, Fla. (Tendler); the Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles (Bystritsky); the Spectrum Neuroscience and Treatment Center, New York (Hollander); the Temerty Centre for Therapeutic Brain Intervention and the Campbell Family Research Institute, Centre for Addiction and Mental Health, and the Department of Psychiatry, University of Toronto, Ontario (Blumberger, Daskalakis); the Department of Psychiatry, University of Florida, Gainesville (Ward); the Department of Psychiatry, Northwell Health, New York (Lapidus); the Department of Psychiatry and Behavioral Health System, Icahn School of Medicine at Mount Sinai, New York (Goodman); the Lindner Center of HOPE, Mason, Ohio (Casuto); the Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati (Casuto); the Department of Psychiatry, University of California San Diego, La Jolla (Feifel); the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (Zohar)
| | - Jeff Daskalakis
- The School of Psychological Science, Tel Aviv University, Tel Aviv, Israel (Carmi); the Department of Life Sciences and the Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva, Israel (Carmi, Barnea-Ygael, Roth, Zangen); Advanced Mental Health Care, Inc., Palm Beach, Fla. (Tendler); the Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles (Bystritsky); the Spectrum Neuroscience and Treatment Center, New York (Hollander); the Temerty Centre for Therapeutic Brain Intervention and the Campbell Family Research Institute, Centre for Addiction and Mental Health, and the Department of Psychiatry, University of Toronto, Ontario (Blumberger, Daskalakis); the Department of Psychiatry, University of Florida, Gainesville (Ward); the Department of Psychiatry, Northwell Health, New York (Lapidus); the Department of Psychiatry and Behavioral Health System, Icahn School of Medicine at Mount Sinai, New York (Goodman); the Lindner Center of HOPE, Mason, Ohio (Casuto); the Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati (Casuto); the Department of Psychiatry, University of California San Diego, La Jolla (Feifel); the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (Zohar)
| | - Herbert Ward
- The School of Psychological Science, Tel Aviv University, Tel Aviv, Israel (Carmi); the Department of Life Sciences and the Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva, Israel (Carmi, Barnea-Ygael, Roth, Zangen); Advanced Mental Health Care, Inc., Palm Beach, Fla. (Tendler); the Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles (Bystritsky); the Spectrum Neuroscience and Treatment Center, New York (Hollander); the Temerty Centre for Therapeutic Brain Intervention and the Campbell Family Research Institute, Centre for Addiction and Mental Health, and the Department of Psychiatry, University of Toronto, Ontario (Blumberger, Daskalakis); the Department of Psychiatry, University of Florida, Gainesville (Ward); the Department of Psychiatry, Northwell Health, New York (Lapidus); the Department of Psychiatry and Behavioral Health System, Icahn School of Medicine at Mount Sinai, New York (Goodman); the Lindner Center of HOPE, Mason, Ohio (Casuto); the Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati (Casuto); the Department of Psychiatry, University of California San Diego, La Jolla (Feifel); the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (Zohar)
| | - Kyle Lapidus
- The School of Psychological Science, Tel Aviv University, Tel Aviv, Israel (Carmi); the Department of Life Sciences and the Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva, Israel (Carmi, Barnea-Ygael, Roth, Zangen); Advanced Mental Health Care, Inc., Palm Beach, Fla. (Tendler); the Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles (Bystritsky); the Spectrum Neuroscience and Treatment Center, New York (Hollander); the Temerty Centre for Therapeutic Brain Intervention and the Campbell Family Research Institute, Centre for Addiction and Mental Health, and the Department of Psychiatry, University of Toronto, Ontario (Blumberger, Daskalakis); the Department of Psychiatry, University of Florida, Gainesville (Ward); the Department of Psychiatry, Northwell Health, New York (Lapidus); the Department of Psychiatry and Behavioral Health System, Icahn School of Medicine at Mount Sinai, New York (Goodman); the Lindner Center of HOPE, Mason, Ohio (Casuto); the Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati (Casuto); the Department of Psychiatry, University of California San Diego, La Jolla (Feifel); the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (Zohar)
| | - Wayne Goodman
- The School of Psychological Science, Tel Aviv University, Tel Aviv, Israel (Carmi); the Department of Life Sciences and the Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva, Israel (Carmi, Barnea-Ygael, Roth, Zangen); Advanced Mental Health Care, Inc., Palm Beach, Fla. (Tendler); the Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles (Bystritsky); the Spectrum Neuroscience and Treatment Center, New York (Hollander); the Temerty Centre for Therapeutic Brain Intervention and the Campbell Family Research Institute, Centre for Addiction and Mental Health, and the Department of Psychiatry, University of Toronto, Ontario (Blumberger, Daskalakis); the Department of Psychiatry, University of Florida, Gainesville (Ward); the Department of Psychiatry, Northwell Health, New York (Lapidus); the Department of Psychiatry and Behavioral Health System, Icahn School of Medicine at Mount Sinai, New York (Goodman); the Lindner Center of HOPE, Mason, Ohio (Casuto); the Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati (Casuto); the Department of Psychiatry, University of California San Diego, La Jolla (Feifel); the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (Zohar)
| | - Leah Casuto
- The School of Psychological Science, Tel Aviv University, Tel Aviv, Israel (Carmi); the Department of Life Sciences and the Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva, Israel (Carmi, Barnea-Ygael, Roth, Zangen); Advanced Mental Health Care, Inc., Palm Beach, Fla. (Tendler); the Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles (Bystritsky); the Spectrum Neuroscience and Treatment Center, New York (Hollander); the Temerty Centre for Therapeutic Brain Intervention and the Campbell Family Research Institute, Centre for Addiction and Mental Health, and the Department of Psychiatry, University of Toronto, Ontario (Blumberger, Daskalakis); the Department of Psychiatry, University of Florida, Gainesville (Ward); the Department of Psychiatry, Northwell Health, New York (Lapidus); the Department of Psychiatry and Behavioral Health System, Icahn School of Medicine at Mount Sinai, New York (Goodman); the Lindner Center of HOPE, Mason, Ohio (Casuto); the Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati (Casuto); the Department of Psychiatry, University of California San Diego, La Jolla (Feifel); the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (Zohar)
| | - David Feifel
- The School of Psychological Science, Tel Aviv University, Tel Aviv, Israel (Carmi); the Department of Life Sciences and the Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva, Israel (Carmi, Barnea-Ygael, Roth, Zangen); Advanced Mental Health Care, Inc., Palm Beach, Fla. (Tendler); the Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles (Bystritsky); the Spectrum Neuroscience and Treatment Center, New York (Hollander); the Temerty Centre for Therapeutic Brain Intervention and the Campbell Family Research Institute, Centre for Addiction and Mental Health, and the Department of Psychiatry, University of Toronto, Ontario (Blumberger, Daskalakis); the Department of Psychiatry, University of Florida, Gainesville (Ward); the Department of Psychiatry, Northwell Health, New York (Lapidus); the Department of Psychiatry and Behavioral Health System, Icahn School of Medicine at Mount Sinai, New York (Goodman); the Lindner Center of HOPE, Mason, Ohio (Casuto); the Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati (Casuto); the Department of Psychiatry, University of California San Diego, La Jolla (Feifel); the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (Zohar)
| | - Noam Barnea-Ygael
- The School of Psychological Science, Tel Aviv University, Tel Aviv, Israel (Carmi); the Department of Life Sciences and the Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva, Israel (Carmi, Barnea-Ygael, Roth, Zangen); Advanced Mental Health Care, Inc., Palm Beach, Fla. (Tendler); the Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles (Bystritsky); the Spectrum Neuroscience and Treatment Center, New York (Hollander); the Temerty Centre for Therapeutic Brain Intervention and the Campbell Family Research Institute, Centre for Addiction and Mental Health, and the Department of Psychiatry, University of Toronto, Ontario (Blumberger, Daskalakis); the Department of Psychiatry, University of Florida, Gainesville (Ward); the Department of Psychiatry, Northwell Health, New York (Lapidus); the Department of Psychiatry and Behavioral Health System, Icahn School of Medicine at Mount Sinai, New York (Goodman); the Lindner Center of HOPE, Mason, Ohio (Casuto); the Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati (Casuto); the Department of Psychiatry, University of California San Diego, La Jolla (Feifel); the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (Zohar)
| | - Yiftach Roth
- The School of Psychological Science, Tel Aviv University, Tel Aviv, Israel (Carmi); the Department of Life Sciences and the Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva, Israel (Carmi, Barnea-Ygael, Roth, Zangen); Advanced Mental Health Care, Inc., Palm Beach, Fla. (Tendler); the Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles (Bystritsky); the Spectrum Neuroscience and Treatment Center, New York (Hollander); the Temerty Centre for Therapeutic Brain Intervention and the Campbell Family Research Institute, Centre for Addiction and Mental Health, and the Department of Psychiatry, University of Toronto, Ontario (Blumberger, Daskalakis); the Department of Psychiatry, University of Florida, Gainesville (Ward); the Department of Psychiatry, Northwell Health, New York (Lapidus); the Department of Psychiatry and Behavioral Health System, Icahn School of Medicine at Mount Sinai, New York (Goodman); the Lindner Center of HOPE, Mason, Ohio (Casuto); the Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati (Casuto); the Department of Psychiatry, University of California San Diego, La Jolla (Feifel); the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (Zohar)
| | - Abraham Zangen
- The School of Psychological Science, Tel Aviv University, Tel Aviv, Israel (Carmi); the Department of Life Sciences and the Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva, Israel (Carmi, Barnea-Ygael, Roth, Zangen); Advanced Mental Health Care, Inc., Palm Beach, Fla. (Tendler); the Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles (Bystritsky); the Spectrum Neuroscience and Treatment Center, New York (Hollander); the Temerty Centre for Therapeutic Brain Intervention and the Campbell Family Research Institute, Centre for Addiction and Mental Health, and the Department of Psychiatry, University of Toronto, Ontario (Blumberger, Daskalakis); the Department of Psychiatry, University of Florida, Gainesville (Ward); the Department of Psychiatry, Northwell Health, New York (Lapidus); the Department of Psychiatry and Behavioral Health System, Icahn School of Medicine at Mount Sinai, New York (Goodman); the Lindner Center of HOPE, Mason, Ohio (Casuto); the Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati (Casuto); the Department of Psychiatry, University of California San Diego, La Jolla (Feifel); the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (Zohar)
| | - Joseph Zohar
- The School of Psychological Science, Tel Aviv University, Tel Aviv, Israel (Carmi); the Department of Life Sciences and the Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva, Israel (Carmi, Barnea-Ygael, Roth, Zangen); Advanced Mental Health Care, Inc., Palm Beach, Fla. (Tendler); the Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles (Bystritsky); the Spectrum Neuroscience and Treatment Center, New York (Hollander); the Temerty Centre for Therapeutic Brain Intervention and the Campbell Family Research Institute, Centre for Addiction and Mental Health, and the Department of Psychiatry, University of Toronto, Ontario (Blumberger, Daskalakis); the Department of Psychiatry, University of Florida, Gainesville (Ward); the Department of Psychiatry, Northwell Health, New York (Lapidus); the Department of Psychiatry and Behavioral Health System, Icahn School of Medicine at Mount Sinai, New York (Goodman); the Lindner Center of HOPE, Mason, Ohio (Casuto); the Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati (Casuto); the Department of Psychiatry, University of California San Diego, La Jolla (Feifel); the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (Zohar)
| |
Collapse
|
18
|
Fineberg NA, Demetrovics Z, Stein DJ, Ioannidis K, Potenza MN, Grünblatt E, Brand M, Billieux J, Carmi L, King DL, Grant JE, Yücel M, Dell'Osso B, Rumpf HJ, Hall N, Hollander E, Goudriaan A, Menchon J, Zohar J, Burkauskas J, Martinotti G, Van Ameringen M, Corazza O, Pallanti S, Chamberlain SR. Manifesto for a European research network into Problematic Usage of the Internet. Eur Neuropsychopharmacol 2018; 28:1232-1246. [PMID: 30509450 PMCID: PMC6276981 DOI: 10.1016/j.euroneuro.2018.08.004] [Citation(s) in RCA: 160] [Impact Index Per Article: 26.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/23/2018] [Revised: 07/18/2018] [Accepted: 08/07/2018] [Indexed: 12/24/2022]
Abstract
The Internet is now all-pervasive across much of the globe. While it has positive uses (e.g. prompt access to information, rapid news dissemination), many individuals develop Problematic Use of the Internet (PUI), an umbrella term incorporating a range of repetitive impairing behaviours. The Internet can act as a conduit for, and may contribute to, functionally impairing behaviours including excessive and compulsive video gaming, compulsive sexual behaviour, buying, gambling, streaming or social networks use. There is growing public and National health authority concern about the health and societal costs of PUI across the lifespan. Gaming Disorder is being considered for inclusion as a mental disorder in diagnostic classification systems, and was listed in the ICD-11 version released for consideration by Member States (http://www.who.int/classifications/icd/revision/timeline/en/). More research is needed into disorder definitions, validation of clinical tools, prevalence, clinical parameters, brain-based biology, socio-health-economic impact, and empirically validated intervention and policy approaches. Potential cultural differences in the magnitudes and natures of types and patterns of PUI need to be better understood, to inform optimal health policy and service development. To this end, the EU under Horizon 2020 has launched a new four-year European Cooperation in Science and Technology (COST) Action Programme (CA 16207), bringing together scientists and clinicians from across the fields of impulsive, compulsive, and addictive disorders, to advance networked interdisciplinary research into PUI across Europe and beyond, ultimately seeking to inform regulatory policies and clinical practice. This paper describes nine critical and achievable research priorities identified by the Network, needed in order to advance understanding of PUI, with a view towards identifying vulnerable individuals for early intervention. The network shall enable collaborative research networks, shared multinational databases, multicentre studies and joint publications.
Collapse
Affiliation(s)
- N A Fineberg
- Hertfordshire Partnership University NHS Foundation Trust, Rosanne House, Welwyn Garden City, Hertfordshire AL8 6HG, UK; Center for Clinical & Health Research Services, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK; School of Clinical Medicine, University of Cambridge, Cambridge, UK.
| | - Z Demetrovics
- Institute of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary
| | - D J Stein
- Department of Psychiatry and Mental Health at the University of Cape Town and South African MRC Unit on Risk & Resilience in Mental Disorders, Cape Town, South Africa
| | - K Ioannidis
- Department of Psychiatry, University of Cambridge, Cambridge, UK; Cambridge & Peterborough NHS Foundation Trust, Cambridge, UK
| | - M N Potenza
- Connecticut Mental Health Center and Departments of Psychiatry, Neuroscience and Child Study Center, Yale School of Medicine, New Haven, USA; Connecticut Council on Problem Gambling, Wethersfield, CT, USA
| | - E Grünblatt
- Department of Child and Adolescent Psychiatry and Psychotherapy, Psychiatric University Hospital Zurich, University of Zurich, Zurich, Switzerland; Neuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland; Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland
| | - M Brand
- General Psychology: Cognition and Center for Behavioral Addiction Research (CeBAR), Department of Computer Science and Applied Cognitive Science Faculty of Engineering, University of Duisburg-Essen, Duisburg, Germany; Erwin L. Hahn Institute for Magnetic Resonance Imaging, Essen, Germany
| | - J Billieux
- Addictive and Compulsive Behaviours Lab, Institute for Health and Behaviour, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Addiction Division, Department of Mental Health and Psychiatry, University Hospitals of Geneva, Switzerland; Centre for Excessive Gambling, Lausanne University Hospitals (CHUV), Lausanne, Switzerland
| | - L Carmi
- School of Psychological Sciences, Tel Aviv University, Tel Aviv, Israel
| | - D L King
- School of Psychology, University of Adelaide, Adelaide, Australia
| | - J E Grant
- Department of Psychiatry, University of Chicago, Chicago, USA
| | - M Yücel
- Monash Institute of Cognitive and Clinical Neurosciences, School of Psychological Sciences, Monash University, Melbourne, Australia
| | - B Dell'Osso
- Department of Pathophysiology and Transplantation, University of Milan, Fondazione IRCCS Ca' Granda and CRC "Aldo Ravelli" for neurotechnology and experimental brain therapeutics, Milan, Italy; Department of Psychiatry, University of Milan, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy; Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA; CRC "Aldo Ravelli" for Neurotechnology and Experimental Brain Therapeutics, University of Milan, Milan, Italy
| | - H J Rumpf
- University of Lübeck, Department of Psychiatry and Psychotherapy, Centre for Integrative Psychiatry, Lübeck, Germany
| | - N Hall
- Center for Clinical & Health Research Services, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK
| | - E Hollander
- Department of Psychiatry and Compulsive, Impulsive and Autism Spectrum Program, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA
| | - A Goudriaan
- Department of Psychiatry, Academisch Medisch Centrum (AMC), University of Amsterdam, Amsterdam, Netherlands; Amsterdam UMC, University of Amsterdam, Department of Psychiatry, Amsterdam Institute for Addiction Research, Meibergdreef 9, Amsterdam, Netherlands; Arkin, Amsterdam, The Netherlands
| | - J Menchon
- Department of Psychiatry, Bellvitge University, Hospital-IDIBELL, University of Barcelona, Cibersam, Barcelona, Spain
| | - J Zohar
- Sackler Medical School, Tel Aviv University, and Chaim Sheba Medical Center Tel Hashomer, Tel Aviv, Israel
| | - J Burkauskas
- Laboratory of Behavioral Medicine, Neuroscience Institute, Lithuanian University of Health Sciences, Palanga, Lithuania
| | - G Martinotti
- Department of Neuroscience, Imaging, Clinical Science, University G.d'Annunzio of Chieti-Pescara, Chieti, Italy
| | - M Van Ameringen
- Department of Psychiatry and Behavioural Neurosciences, McMaster University, Ontario, Canada
| | - O Corazza
- Center for Clinical & Health Research Services, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK
| | - S Pallanti
- Albert Einstein College of Medicine, New York, USA; University of Florence, Italy
| | - S R Chamberlain
- Department of Psychiatry, University of Cambridge, Cambridge, UK; Cambridge & Peterborough NHS Foundation Trust, Cambridge, UK
| |
Collapse
|
19
|
Grant JE, Fineberg N, van Ameringen M, Cath D, Visser H, Carmi L, Pallanti S, Hollander E, van Balkom AJLM. New treatment models for compulsive disorders. Eur Neuropsychopharmacol 2016; 26:877-84. [PMID: 26621260 DOI: 10.1016/j.euroneuro.2015.11.008] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/25/2015] [Revised: 08/12/2015] [Accepted: 11/08/2015] [Indexed: 01/21/2023]
Abstract
Obsessive compulsive disorder (OCD) as well as related disorders such as body dysmorphic disorder, tic disorder, and trichotillomania are all common and often debilitating. Although treatments are available, more effective approaches to these problems are needed. Thus this review article presents what is currently known about OCD and related disorders and suggests that understanding OCD more broadly as a compulsive disorder may allow for more effective treatment options. Toward that goal, the review presents new models of psychopharmacology and psychotherapy, as well as new brain stimulation strategies. Treatment advances, grounded in the neuroscience, have promise in advancing treatment response for OCD as well as other disorders of compulsivity.
Collapse
Affiliation(s)
- Jon E Grant
- Department of Psychiatry & Behavioral Neuroscience, University of Chicago, Pritzker School of Medicine, 5841 S. Maryland Avenue, MC 3077, Chicago, IL 60637, USA.
| | - Naomi Fineberg
- Highly Specialized OCD and BDD Services, Hertfordshire Partnership University NHS Foundation Trust and University of Hertfordshire, UK
| | - Michael van Ameringen
- Department of Psychiatry and Behavioural Neurosciences, McMaster University and MacAnxiety Research Centre, Hamilton, Ontario, Canada
| | - Danielle Cath
- Utrecht University and Altrecht Academic Anxiety Disorders Center, Utrecht, The Netherlands
| | - Henny Visser
- Innova Research Centre, Mental Health Care Institute GGZ Centraal, Ermelo, The Netherlands
| | - Lior Carmi
- Department of Psychology, Tel Aviv University, Tel Aviv, Israel; Department of Psychiatry, Chaim Sheba Medical Center, Tel Hashomer, Israel
| | - Stefano Pallanti
- Department of Psychiatry and Behavioral Sciences UC Davis Health System, Albert Einstein College of Medicine and Montefiore Medical Center, Sacramento, CA, USA
| | - Eric Hollander
- Department of Psychiatry, Albert Einstein Medical School, Montefiore Medical Center, New York City, NY, USA
| | - Anton J L M van Balkom
- Department of Psychiatry and EMGO(+) Institute, VU-University Medical Centre and GGZ ingest, Amsterdam, The Netherlands
| |
Collapse
|
20
|
Portnoy E, Holly B, Weiss C, Carmi L, Lessne M, Schlachter T, Tamrazi A. Massive pulmonary embolism thrombolysis: real-time clinical parameters suggest early onset of treatment efficacy. J Vasc Interv Radiol 2015. [DOI: 10.1016/j.jvir.2014.12.206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|